iBio, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- iBio, Inc. (IBIO) is a preclinical-stage biotechnology company that leverages artificial intelligence and advanced computational biology platforms to develop precision antibodies and next-generation biopharmaceuticals targeting cardiometabolic diseases, obesity, immuno-oncology indications including solid tumors in breast, lung, colorectal and pancreatic cancers as well as glioblastoma, and other hard-to-treat conditions; its core offerings include an AI-driven antibody discovery platform featuring proprietary 3D epitope modeling, machine learning-enabled epitope steering for difficult targets, monoclonal antibody optimization to enhance developability and safety profiles, and a fully integrated technology stack for rapid drug candidate identification with extended half-life properties and reduced dosing frequency. The company advances a rapidly expanding preclinical pipeline of therapeutic candidates designed to preserve muscle mass during weight loss, prevent weight regain, complement GLP-1 therapies, address metabolic syndrome-related heart disease, and enable higher-quality obesity treatments with improved tolerability for long-term use. Founded in 2008 through a merger involving plant-based technology assets and headquartered in San Diego, California, iBio operates primarily in the United States with a focus on transforming drug discovery timelines and partnering for clinical advancement. Recent developments include a transformative AI drug discovery collaboration and multiple licensing agreements with AstralBio for first-in-class antibodies targeting Activin E and anti-myostatin programs to bolster its cardiometabolic and obesity pipeline; preclinical in vivo data for IBIO-600 demonstrating extended half-life and muscle growth alongside interim Activin E results; executive appointments of Dr. Martin Brenner as CEO, Felipe Duran as CFO, and Kristi Sarno as SVP of Business Development; closure of its Texas manufacturing facility sale; securing $6.2 million in gross proceeds from warrant exercises in April 2025; Nasdaq stock exchange listing; new investments from board members and officers; expansion of its tech stack with EngageTx and addition of a TROP-2 bispecific to the pipeline; a research collaboration with the National Institutes of Health; and discovery of novel CD3 T-cell binding antibodies using its patented AI platform alongside advancement of its anti-CCR8 program to in vivo testing, all within the past two years to support strategic growth in precision medicine.
Company News
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
iBio to Participate in Upcoming Healthcare Investor Conferences
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
iBio (NASDAQ:IBIO) versus Gemini Therapeutics (NASDAQ:GMTX) Critical Review
iBio to Participate in Upcoming Investor Conferences
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX)
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)
iBio (NYSEMKT:IBIO) Trading 8.3% Higher – Here’s Why
iBio Announces $26 Million Private Placement